CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies.
Le Cann M, Bouhour F, Viala K, Simon L, Tard C, Rossi C, Morel G, Lagrange E, Magy L, Créange A, Michaud M, Franques J, Echaniz-Laguna A, Antoine JC, Baron M, Arnulf B, Puma A, Delmont E, Maisonobe T, Leblond V, Roos-Weil D.
Le Cann M, et al. Among authors: franques j.
Blood. 2020 Nov 19;136(21):2428-2436. doi: 10.1182/blood.2020007092.
Blood. 2020.
PMID: 32959046
Free article.